Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
|
US |
|
Tsingtao Brewery Co Ltd
OTC:TSGTY
|
CN |
|
Agricultural Bank of China Ltd
OTC:ACGBY
|
CN |
|
M
|
Mondelez International Inc
SGO:MDLZ
|
US |
|
N
|
Note AB (publ)
LSE:0GSS
|
SE |
|
Applied Materials Inc
NASDAQ:AMAT
|
US |
|
East Japan Railway Co
TSE:9020
|
JP |
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals is a biopharmaceutical company that focuses on rare genetic diseases that cause severe obesity. Its main product is Imcivree, a prescription medicine used for certain patients whose body’s appetite-control pathway does not work properly. The company also develops follow-on treatments aimed at the same biology, especially the melanocortin-4 receptor pathway that helps regulate hunger and body weight. Rhythm sells to specialist doctors, hospitals, and specialty pharmacies that treat patients with these rare conditions. Its money comes mainly from selling its approved medicine, with additional value tied to developing and potentially expanding the use of its drug in other genetic obesity disorders. Because these diseases are uncommon and often diagnosed by specialists, the company relies on a focused commercial model rather than a broad primary-care sales force. What makes Rhythm different is that it is built around a narrow set of inherited disorders where the root problem is biologic, not lifestyle-driven. That gives the company a highly specialized role in the rare disease market: it works with physicians to identify the right patients, support diagnosis, and provide treatment for conditions that have few targeted options. For investors, the key point is that Rhythm’s business depends on proving and commercializing medicines for very specific genetic patient groups.
Rhythm Pharmaceuticals is a biopharmaceutical company that focuses on rare genetic diseases that cause severe obesity. Its main product is Imcivree, a prescription medicine used for certain patients whose body’s appetite-control pathway does not work properly. The company also develops follow-on treatments aimed at the same biology, especially the melanocortin-4 receptor pathway that helps regulate hunger and body weight.
Rhythm sells to specialist doctors, hospitals, and specialty pharmacies that treat patients with these rare conditions. Its money comes mainly from selling its approved medicine, with additional value tied to developing and potentially expanding the use of its drug in other genetic obesity disorders. Because these diseases are uncommon and often diagnosed by specialists, the company relies on a focused commercial model rather than a broad primary-care sales force.
What makes Rhythm different is that it is built around a narrow set of inherited disorders where the root problem is biologic, not lifestyle-driven. That gives the company a highly specialized role in the rare disease market: it works with physicians to identify the right patients, support diagnosis, and provide treatment for conditions that have few targeted options. For investors, the key point is that Rhythm’s business depends on proving and commercializing medicines for very specific genetic patient groups.
Revenue: Rhythm reported $60.1 million in global net revenues in Q1 2026, up 5% sequentially, with growth driven mainly by BBS and a strong international contribution.
HO Launch: The U.S. launch of IMCIVREE for acquired hypothalamic obesity started strongly, with more than 150 start forms in the first six weeks, about 110 unique prescribers, and early reimbursement approvals.
Europe and Japan: The company secured European marketing authorization for HO earlier than expected and now expects country launches to begin in 2027; in Japan, the PMDA has accepted the NDA and Rhythm is targeting approval and launch by the end of 2026.
Costs: Operating expenses rose as Rhythm expanded sales, marketing, Japan operations, and pipeline work; full-year 2026 operating expense guidance was unchanged.
Pipeline: Management said upcoming milestones include PWS data at endo in June, 718 data midyear, and a goal to start a Phase III HO trial with bivamelagon by the end of 2026.
Confidence: Executives repeatedly said the launch looks better than expected so far, emphasizing broad prescriber interest, payer receptivity, and a launch pace that is faster than BBS.
